Thyroid cancer is the most frequent endocrine neoplasia, and its incidence is rapidly increasing. Although most of the thyroid tumors are differentiated carcinomas, the survival rate can vary widely, accounting for their different phenotypes and sensitivity to standard therapies. Recent research has put some light on the molecular genetics of benign and the various types of malignant thyroid tumors. Knowledge and understanding of the underlying molecular pathology of these conditions may have diagnostic or therapeutic clinical implications.

We invite investigators to contribute both original research articles and review articles that will stimulate the ongoing efforts to understand the molecular mechanisms underlying thyroid tumorigenesis. We are particularly interested in articles describing the identification of new biomarkers, new insight into the molecular genetics of thyroid tumors, in vitro and in vivo models for thyroid tumor development and their treatment, and current clinical concepts concerning the treatment of various types of malignant thyroid tumors based on molecular pathology. Potential topics include but are not limited to:

• Identification of biomarkers that differentiate between benign and malignant thyroid tumors
• Identification of biomarkers that facilitate identification of various types of malignant thyroid tumors
• Identification of biomarkers that predict local or distant metastases
• In vitro research on molecular-based therapy
• In vivo research on molecular-based therapy

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/jtr/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: